OncoMatch/Clinical Trials/NCT04305548
Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
Is NCT04305548 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Trabectedin for mesenchymal chondrosarcoma.
Treatment: Trabectedin — Prospective, uncontrolled, investigator-initiated, phase II clinical study to explore the activity of trabectedin in a population of patients aged ≥16 years with progressive, advanced (locally advanced or metastatic)
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: HEY1 HEY1-NCOA2 fusion
documented presence of HEY1-NCOA2 fusion
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anthracycline — advanced phase
pre-treated with at least one prior chemotherapy treatment containing anthracyclines for the advanced phase of disease and with a maximum of 3 lines
Cannot have received: radiation therapy
Previous treatment with radiation therapy within 14 days of first day of study drug dosing
Cannot have received: radiation therapy
Previous radiotherapy to 25% of the bone marrow
Lab requirements
Blood counts
Adequate bone marrow function
Kidney function
Adequate organ function
Liver function
Adequate organ function
Cardiac function
Cardiac ejection fraction ≥50% as measured by echocardiogram; Grade III/IV cardiac problems as defined by the New York Heart Association Criteria [excluded]
Adequate bone marrow function; Adequate organ function; Cardiac ejection fraction ≥50% as measured by echocardiogram; Grade III/IV cardiac problems as defined by the New York Heart Association Criteria [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify